Interventional radiology for liver diseases

Defreyne, Luc

doi:10.1007/s00330-020-07356-w

Cited by 6 publications

(6 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…DC obtained in this study was higher than that reported for conventional TACE (52-65.4%) or TACE performed with other microspheres: DC Bead (Boston Scientific, MA, USA) (63.8%), HepaSphere (Merit Medical, UT, USA) (53.8%) and Embozene Tandem beads (Varian Medical Systems, CA, USA) (81%) [27][28][29][30][31]. This may be due to the physio-mechanical properties of the LifePearl™ core material, which allows higher drug release in comparison with other drug-eluting microspheres, as shown in the in vitro comparative study of LifePearl ™ , DC Bead, HepaSphere and Embozene Tandem microspheres, which eluted 30 ± 5%, 21 ± 2%, 8 ± 3% and 6 ± 0%, respectively, of the loaded doxorubicin [16].…”

Section: Discussioncontrasting

confidence: 65%

Unresectable hepatocellular carcinoma treatment with doxorubicin-eluting polyethylene glycol microspheres: a single-center experience

et al. 2021

View full text Add to dashboard Cite

Background: Transarterial chemoembolization (TACE) is indicated for unresectable hepatocellular carcinoma. Methods: This was a retrospective study of 50 hepatocellular carcinoma patients treated with TACE using doxorubicin-loaded LifePearl™ to investigate the safety and efficacy of TACE. Results: There was no 30-day mortality, and limited adverse events were reported. At best tumor response, complete response and disease control were 58% and 94%, respectively, with a median of 4.5 months of follow-up. Median overall survival was 33.8 months. Patients with Barcelona Clinic Liver Cancer stage 0 and stage A at best tumor response showed a higher complete response rate (83%) than patients with Barcelona Clinic Liver Cancer stage B (complete response: 50%; p = 0.0414). Conclusion: Doxorubicin-loaded LifePearl™ TACE might be an effective treatment, with a good safety profile, for patients with early/intermediate-stage hepatocellular carcinoma. Further prospective data, especially with a small cohort of selected patients, are required to confirm these results.

show abstract

Section: Discussioncontrasting

confidence: 65%

Unresectable hepatocellular carcinoma treatment with doxorubicin-eluting polyethylene glycol microspheres: a single-center experience

et al. 2021

View full text Add to dashboard Cite

show abstract

“…It has been established that complete Lipiodol retention implies a more thorough reduction in tumor vascularity, which can reduce the tissue cooling effect and potentiate the efficacy of thermal ablation [ 20 ]. However, revascularization of the tumor and Lipiodol washout may occur over time, which may amplify the tissue cooling effect, thus reducing the treatment efficacy of ablation, even in lesions with complete Lipiodol retention [ 6 , 21 , 22 ]. As previously described, the heat-sink effect is more common in lesions with perivascular location, and embolization of the tumor-feeding arteries may reduce the heat-sink effect [ 4 , 8 , 21 ].…”

Section: Discussionmentioning

confidence: 99%

“…Various techniques, such as the combination of transarterial chemoembolization (TACE) and ablation, have been proposed to improve the treatment efficacy of ablation for larger tumors [ 5 ]. Generally, TACE may decrease hepatic artery inflow, which reduces the “heat-sink” effect, resulting in an extended ablation area [ 6 ]. In addition, tumor visualization can be improved by iodized oil (Lipiodol, Guerbet Group, Villepinte, France) retention when performing ablation under computed tomography (CT) guidance [ 7 ].…”

Section: Introductionmentioning

confidence: 99%

Combined transarterial iodized oil injection and computed tomography-guided thermal ablation for hepatocellular carcinoma: utility of the iodized oil retention pattern

et al. 2021

View full text Add to dashboard Cite

Purpose To investigate whether the iodized oil (Lipiodol, Guerbet Group, Villepinte, France) retention pattern influences the treatment efficacy of combined transarterial Lipiodol injection (TLI) and thermal ablation in patients with hepatocellular carcinoma (HCC). Methods Data of 198 patients (280 HCC lesions), who underwent TLI plus computed tomography (CT)-guided thermal ablation at three separate medical institutions between June 2014 and September 2020, were reviewed and analyzed. The Lipiodol retention pattern was classified as complete or incomplete based on non-enhanced CT at the time of ablation. The primary outcome was local recurrence-free survival (LRFS) for lesions; the secondary outcome was overall survival (OS) for patients. Propensity score matching (PSM) was performed using a caliper width of 0.1 between the two groups. Differences in LRFS and OS between the two groups were compared using the log-rank test. Results A total of 133 lesions exhibited a complete Lipiodol retention pattern, while 147 exhibited an incomplete pattern. After PSM analysis of baseline characteristics of the lesions, 121 pairs of lesions were matched. LRFS was significantly longer for lesions exhibiting complete retention than for those exhibiting incomplete retention (P = 0.030). After PSM analysis of patient baseline characteristics, 74 pairs of patients were matched. There was no significant difference in OS between the two groups (P = 0.456). Conclusion Lipiodol retention patterns may influence the treatment efficacy of combined TLI and thermal ablation for HCC lesions. However, a survival benefit for the Lipiodol retention pattern among HCC patients was not observed and needs further confirmation.

show abstract

“…In the examination of a patient with known hepatitis C through a subcostal route, an ultrasound image shows real-time percutaneous needle placement for a random liver biopsy (5) .…”

Section: Figure (1)mentioning

confidence: 99%

Interventional Radiology in the Management of Liver Diseases: Review Article

Hassaf¹

2022

The Egyptian Journal of Hospital Medicine

View full text Add to dashboard Cite

Background: Infections of the liver are common and can continue a long time. Furthermore, the fatality rate associated with chronic liver illnesses remains high, despite continuing development of novel diagnostic and treatment processes. As a result, significant attempts to improve imaging techniques have been made, notably in this decade. The morphology, circulation, metabolism, parenchymal texture, fibrosis, and/or tumour viability of the liver can all be investigated using contemporary imaging methods. Some of the novel imaging techniques and procedures that have made it possible to monitor liver function include magnetic resonance perfusion, magnetic resonance elastography, and dual-energy computed tomography (CT). Objective:The study aimed to highlight on improved imaging techniques and advanced interventional radiology (IR) technologies, new multimodality treatments for liver illnesses have been developed. Methods: PubMed and Google scholar were searched using the following keywords: Liver diseases, CT, MRI and liver treatments. The authors also screened references from the relevant literature, including all the identified studies and reviews, only the most recent or complete study was included, and in peer-reviewed articles between February 2010 and July 2021.Conclusion: Finally, this special review reviewed recent breakthroughs in both diagnostic and interventional radiology, providing us with useful perspectives in this rapidly evolving discipline.

show abstract

Interventional radiology for liver diseases

Cited by 6 publications

References 57 publications

Unresectable hepatocellular carcinoma treatment with doxorubicin-eluting polyethylene glycol microspheres: a single-center experience

Unresectable hepatocellular carcinoma treatment with doxorubicin-eluting polyethylene glycol microspheres: a single-center experience

Combined transarterial iodized oil injection and computed tomography-guided thermal ablation for hepatocellular carcinoma: utility of the iodized oil retention pattern

Interventional Radiology in the Management of Liver Diseases: Review Article

Contact Info

Product

Resources

About